Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.
| Website | https://www.avencell.com |
| Revenue | $7.8 million |
| Employees | 65 (53 on RocketReach) |
| Address | 51 Moulton St, Cambridge, Massachusetts 02138, US |
| Industry | Biotechnology |
| Keywords | Immunotherapy, Cancer Treatment, Oncology, Pharmaceutical, Biotechnology, Drug Development, Clinical Trials, Cancer Research, Medical Research, Healthcare, Biopharma, Therapeutics, Next Generation Therapies, Precision Medicine, Rare Cancers, Advanced Therapies, Immuno Oncology, Cell Therapy |
| Competitors | Roche, AbbVie, Bristol Myers Squibb, Amgen, Novartis, Celltrion Inc, Genentech, Sanofi, Biogen, Merck AH +42 more (view full list) |
Looking for a particular AvenCell employee's phone or email?
The AvenCell annual revenue was $7.8 million in 2026.
Andrew Schiermeier is the CEO of AvenCell.
53 people are employed at AvenCell.
AvenCell is based in Cambridge, Massachusetts.